The myeloid translocation gene 16 product MTG16 is found in multiple transcription factor–containing complexes as a regulator of gene expression implicated in development and tumorigenesis. A stable Tet-On system for doxycycline–dependent expression of MTG16 was established in B-lymphoblastoid Raji cells to unravel its molecular functions in transformed cells. A noticeable finding was that expression of certain genes involved in tumor cell metabolism including 6-phosphofructo-2-kinase/fructose-2,6-bi？phosphatase3 and 4 (PFKFB3 and PFKFB4), and pyruvate dehydrogenase kinase isoenzyme 1 (PDK1) was rapidly diminished when MTG16 was expressed. Furthermore, hypoxia–stimulated production of PFKFB3, PFKFB4 and PDK1 was inhibited by MTG16 expression. The genes in question encode key regulators of glycolysis and its coupling to mitochondrial metabolism and are commonly found to be overexpressed in transformed cells. The MTG16 Nervy Homology Region 2 (NHR2) oligomerization domain and the NHR3 protein–protein interaction domain were required intact for inhibition of PFKFB3, PFKFB4 and PDK1 expression to occur. Expression of MTG16 reduced glycolytic metabolism while mitochondrial respiration and formation of reactive oxygen species increased. The metabolic changes were paralleled by increased phosphorylation of mitogen–activated protein kinases, reduced levels of amino acids and inhibition of proliferation with a decreased fraction of cells in S-phase. Overall, our findings show that MTG16 can serve as a brake on glycolysis, a stimulator of mitochondrial respiration and an inhibitor of cell proliferation. Hence, elevation of MTG16 might have anti–tumor effect.
References
[1]
Feinstein PG, Kornfeld K, Hogness DS, Mann RS (1995) Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue. Genetics 140: 573–586.
[2]
Erickson P, Gao J, Chang KS, Look T, Whisenant E, et al. (1992) Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 80: 1825–1831.
[3]
Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, et al. (1993) The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12: 2715–2721.
[4]
Nisson PE, Watkins PC, Sacchi N (1993) Transcriptionally active chimeric gene derived from the fusion of the AML gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet 66: 81.
[5]
Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, et al. (1998) The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. Blood 91: 4028–4037.
[6]
Guastadisegni MC, Lonoce A, Impera L, Di Terlizzi F, Fugazza G, et al. (2010) CBFA2T2 and C20orf112: two novel fusion partners of RUNX1 in acute myeloid leukemia. Leukemia 24: 1516–1519.
[7]
Rossetti S, Hoogeveen AT, Sacchi N (2004) The MTG proteins: chromatin repression players with a passion for networking. Genomics 84: 1–9.
[8]
Melnick AM, Westendorf JJ, Polinger A, Carlile GW, Arai S, et al. (2000) The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Mol Cell Biol 20: 2075–2086.
[9]
Salat D, Liefke R, Wiedenmann J, Borggrefe T, Oswald F (2008) ETO, but not leukemogenic fusion protein AML1/ETO, augments RBP-Jkappa/SHARP-mediated repression of notch target genes. Mol Cell Biol 28: 3502–3512.
[10]
Goardon N, Lambert JA, Rodriguez P, Nissaire P, Herblot S, et al. (2006) ETO2 coordinates cellular proliferation and differentiation during erythropoiesis. EMBO J 25: 357–366.
[11]
McGhee L BJ, Elliott L, Grimes HL, Kazanjian A, Davis JN, Meyers S (2003) Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism. J Cell Biochem 89: 1005–1018.
[12]
Engel ME, Nguyen HN, Mariotti J, Hunt A, Hiebert SW (2010) Myeloid translocation gene 16 (MTG16) interacts with Notch transcription complex components to integrate Notch signaling in hematopoietic cell fate specification. Mol Cell Biol 30: 1852–1863.
[13]
Hunt A, Fischer M, Engel ME, Hiebert SW (2011) Mtg16/Eto2 Contributes to Murine T-Cell Development. Molecular and Cellular Biology 31: 2544–2551.
[14]
Lindberg SR, Olsson A, Persson AM, Olsson I (2005) The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation. Exp Hematol 33: 189–198.
[15]
Fischer MA, Moreno-Miralles I, Hunt A, Chyla BJ, Hiebert SW (2012) Myeloid translocation gene 16 is required for maintenance of haematopoietic stem cell quiescence. EMBO J 31: 1494–1505.
[16]
Hamlett I, Draper J, Strouboulis J, Iborra F, Porcher C, et al. (2008) Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. Blood 112: 2738–2749.
[17]
Chyla BJ, Moreno-Miralles I, Steapleton MA, Thompson MA, Bhaskara S, et al. (2008) Deletion of Mtg16, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation. Molecular and Cellular Biology 28: 6234–6247.
[18]
Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, et al. (2002) CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Research 62: 4599–4604.
[19]
Bais AJ, Gardner AE, McKenzie OLD, Callen DF, Sutherland GR, et al.. (2004) Aberrant CBFA2T3B gene promoter methylation in breast tumors. Molecular Cancer 3..
[20]
Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.
[21]
Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.
Ralph P, Moore MAS, Nilsson K (1976) Lysozyme Synthesis by Established Human and Murine Histiocytic Lymphoma Cell Lines. Journal of Experimental Medicine 143: 1528–1533.
[24]
Martin P, Papayannopoulou T (1982) HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 216: 1233–1235.
[25]
Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, et al. (1989) Establishment and Characterization of a Unique Human Cell-Line That Proliferates Dependently on Gm-Csf, Il-3, or Erythropoietin. Journal of Cellular Physiology 140: 323–334.
[26]
Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, et al. (1985) Establishment of a Novel Human Megakaryoblastic Leukemia-Cell Line, Meg-01, with Positive Philadelphia-Chromosome. Blood 66: 1384–1392.
[27]
Asou H, Tashiro S, Hamamoto K, Otsuji A, Kita K, et al. (1991) Establishment of a Human Acute Myeloid-Leukemia Cell-Line (Kasumi-1) with 8-21 Chromosome-Translocation. Blood 77: 2031–2036.
[28]
Gallagher R, Collins S, Trujillo J, Mccredie K, Ahearn M, et al. (1979) Characterization of the Continuous, Differentiating Myeloid Cell-Line (Hl-60) from a Patient with Acute Promyelocytic Leukemia. Blood 54: 713–733.
[29]
Jensen FC, Girardi AJ, Gilden RV, Koprowski H (1964) Infection of Human and Simian Tissue Cultures with Rous Sarcoma Virus. Proc Natl Acad Sci U S A 52: 53–59.
[30]
Olsson A, Olsson I, Dhanda RS (2008) Transcriptional repression by leukaemia-associated ETO family members can be independent of oligomerization and coexpressed hSIN3B and N-CoR. Biochim Biophys Acta 1779: 590–598.
[31]
Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
[32]
Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116–5121.
[33]
Ginzinger DG (2002) Gene quantification using real-time quantitative PCR: An emerging technology hits the mainstream. Experimental Hematology 30: 503–512.
[34]
Lindberg SR OA, Persson AM, Olsson I (2003) Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins. Eur J Haematol 71: 439–447.
[35]
Malmgren S, Nicholls DG, Taneera J, Bacos K, Koeck T, et al. (2009) Tight coupling between glucose and mitochondrial metabolism in clonal beta-cells is required for robust insulin secretion. J Biol Chem 284: 32395–32404.
[36]
Corda S, Laplace C, Vicaut E, Duranteau J (2001) Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 24: 762–768.
[37]
Spegel P, Danielsson APH, Bacos K, Nagorny CLF, Moritz T, et al. (2010) Metabolomic analysis of a human oral glucose tolerance test reveals fatty acids as reliable indicators of regulated metabolism. Metabolomics 6: 56–66.
[38]
Jonsson P, Johansson ES, Wuolikainen A, Lindberg J, Schuppe-Koistinen I, et al. (2006) Predictive metabolite profiling applying hierarchical multivariate curve resolution to GC-MS datas - A potential tool for multi-parametric diagnosis. Journal of Proteome Research 5: 1407–1414.
[39]
Chorell E, Moritz T, Branth S, Antti H, Svensson MB (2009) Predictive Metabolomics Evaluation of Nutrition-Modulated Metabolic Stress Responses in Human Blood Serum During the Early Recovery Phase of Strenuous Physical Exercise. Journal of Proteome Research 8: 2966–2977.
[40]
Crissman HA, Steinkamp JA (1973) Rapid, simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations. J Cell Biol 59: 766–771.
[41]
Loew R, Heinz N, Hampf M, Bujard H, Gossen M (2010) Improved Tet-responsive promoters with minimized background expression. BMC Biotechnol 10: 81.
[42]
Chevallier N, Corcoran CM, Lennon C, Hyjek E, Chadburn A, et al. (2004) ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood 103: 1454–1463.
[43]
Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230–233.
[44]
Minchenko O, Opentanova I, Caro J (2003) Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bi？sphosphatasegene family (PFKFB-1-4) expression in vivo. FEBS Lett 554: 264–270.
[45]
Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H (2004) Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-bi？phosphatase-4gene via hypoxia-inducible factor-1alpha activation. FEBS Lett 576: 14–20.
[46]
Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177–185.
[47]
Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
[48]
Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, et al. (2010) Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466: 869–873.
[49]
Bensinger SJ, Christofk HR (2012) New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 23: 352–361.
[50]
Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, et al. (1999) An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A 96: 3047–3052.
[51]
Okar DA, Manzano A, Navarro-Sabate A, Riera L, Bartrons R, et al. (2001) PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci 26: 30–35.
[52]
Okar DA, Lange AJ (1999) Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors 10: 1–14.
[53]
Holness MJ, Sugden MC (2003) Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem Soc Trans 31: 1143–1151.
[54]
Slekar KH, Kosman DJ, Culotta VC (1996) The yeast copper zinc superoxide dismutase and the pentose phosphate pathway play overlapping roles in oxidative stress protection. Journal of Biological Chemistry 271: 28831–28836.
[55]
Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–40.
[56]
Karin M GE (2005) From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57: 283–295.
[57]
Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, et al. (1998) The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1. Mol Cell Biol 18: 846–858.
[58]
Wei Y, Liu S, Lausen J, Woodrell C, Cho S, et al. (2007) A TAF4-homology domain from the corepressor ETO is a docking platform for positive and negative regulators of transcription. Nat Struct Mol Biol 14: 653–661.
[59]
Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer AB (2001) Multiple regions of ETO cooperate in transcriptional repression. J Biol Chem 276: 9889–9895.
[60]
Gelmetti V ZJ, Fanelli M, Minucci S, Pelicci PG, Lazar MA (1998) Aberrant recruitment of the nuclear receptor co-repressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18: 7185–7191.
[61]
Lutterbach B SD, Schuetz J, Hiebert SW (1998) The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol 18: 3604–3611.
[62]
Liu Y, Cheney MD, Gaudet JJ, Chruszcz M, Lukasik SM, et al. (2006) The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 9: 249–260.
[63]
Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG (2004) E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305: 1286–1289.
[64]
Atsumi T CJ, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bi？sphosphatase(iPFK-2; PFKFB3) in human cancers. Cancer Res 62: 5881–5887.
[65]
Minchenko A LI, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bi？sphosphatase-3(PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277: 6183–6187.
[66]
Yalcin A TS, Clem B, Chesney J (2009) Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bi？sphosphatasesin cancer. Exp Mol Pathol 86: 174–179.
[67]
Dunaway GA, Kasten TP, Sebo T, Trapp R (1988) Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem J 251: 677–683.
[68]
Krus U, Kotova O, Spegel P, Hallgard E, Sharoyko VV, et al. (2010) Pyruvate dehydrogenase kinase 1 controls mitochondrial metabolism and insulin secretion in INS-1 832/13 clonal beta-cells. Biochem J 429: 205–213.
[69]
Wu M NA, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, Chomicz S, Ferrick DA (2006) Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Pysiol Cell Physiol 292: C125–136.
[70]
Cuadrado A, Nebreda AR (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429: 403–417.
[71]
Rossetti S, Hoogeveen AT, Esposito J, Sacchi N (2010) Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesis. J Cell Mol Med 14: 1358–1370.
